CTLA-4 and PD-1 pathway blockade: combinations in the clinic

被引：186

作者：

Callahan, Margaret K. ^{[1
,2
]}

Postow, Michael A. ^{[1
,2
]}

Wolchok, Jedd D. ^{[1
,2
,3
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Melanoma & Immunotherapeut Serv, New York, NY 10065 USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, New York, NY 10065 USA

来源：

FRONTIERS IN ONCOLOGY | 2015年 / 4卷

关键词：

CLTA-4; PD-1; ipilimumab; nivolumab; immunotherapy; T-CELLS; SAFETY; IPILIMUMAB; NIVOLUMAB; RESPONSES; ANTI-PD-1; ANTIBODY; MELANOMA;

D O I：

10.3389/fonc.2014.00385

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy.These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the monotherapy setting, the field is moving in the direction of testing novel combinations.

引用

页数：6

共 50 条

[1] Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
De Silva, Pushpamali
Aiello, Marco
Gu-Trantien, Chunyan
Migliori, Edoardo
Willard-Gallo, Karen
Solinas, Cinzia
[J]. INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (01) : 31 - 41
[2] PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon, Tawee
Gray, Jhanelle E.
Antonia, Scott J.
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (03) : 305 - 312
[3] PD-1 and CTLA-4: Two checkpoints, one pathway?
Walker, Lucy S. K.
[J]. SCIENCE IMMUNOLOGY, 2017, 2 (11)
[4] Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations
Baksh, Kathryn
Weber, Jeffrey
[J]. SEMINARS IN ONCOLOGY, 2015, 42 (03) : 363 - 377
[5] At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, Andrew M.
Thompson, Craig B.
[J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2013, 94 (01) : 25 - 39
[6] Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition
Sun, Michel M.
Levinson, Ralph D.
Filipowicz, Artur
Anesi, Stephen
Kaplan, Henry J.
Wang, Wei
Goldstein, Debra A.
Gangaputra, Sapna
Swan, Robert T.
Sen, H. Nida
Gordon, Lynn K.
[J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2020, 28 (02) : 217 - 227
[7] Blockade of PD-1 and CTLA-4: A potent immunotherapeutic approach for hepatocellular carcinoma
Hou, Kai
Xu, Xiaohui
Ge, Xin
Jiang, Jiacen
Ouyang, Fan
[J]. BIOFACTORS, 2024, 50 (02) : 250 - 265
[8] GENERALIZABILITY OF POTENTIAL BIOMARKERS OF RESPONSE TO CTLA-4 AND PD-1 BLOCKADE THERAPY IN CANCER
Bortone, Dante
Vensko, Steven
Entwistle, Sarah
Cogdill, Alexandria
Monette, Anne
Najjar, Yana
Sweis, Randy
Tschernia, Nicholas
Wennerberg, Erik
Bommareddy, Praveen
Haymaker, Cara
Khan, Uqba
McGee, Heather
Park, Wungki
Sater, Houssein
Spencer, Christine
Ascierto, Maria
Barsan, Valentin
Popat, Vinita
Valpione, Sara
Wells, Danny
Thorsson, Vesteinn
Zappasodi, Roberta
Rudqvist, Nils
Vincent, Benjamin
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A46 - A47
[9] Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Andrews, Miles C.
Duong, Connie P. M.
Gopalakrishnan, Vancheswaran
Iebba, Valerio
Chen, Wei-Shen
Derosa, Lisa
Khan, Md Abdul Wadud
Cogdill, Alexandria P.
White, Michael G.
Wong, Matthew C.
Ferrere, Gladys
Fluckiger, Aurelie
Roberti, Maria P.
Opolon, Paule
Alou, Maryam Tidjani
Yonekura, Satoru
Roh, Whijae
Spencer, Christine N.
Curbelo, Irina Fernandez
Vence, Luis
Reuben, Alexandre
Johnson, Sarah
Arora, Reetakshi
Morad, Golnaz
Lastrapes, Matthew
Baruch, Erez N.
Little, Latasha
Gumbs, Curtis
Cooper, Zachary A.
Prieto, Peter A.
Wani, Khalida
Lazar, Alexander J.
Tetzlaff, Michael T.
Hudgens, Courtney W.
Callahan, Margaret K.
Adamow, Matthew
Postow, Michael A.
Ariyan, Charlotte E.
Gaudreau, Pierre-Olivier
Nezi, Luigi
Raoult, Didier
Mihalcioiu, Catalin
Elkrief, Arielle
Pezo, Rossanna C.
Haydu, Lauren E.
Simon, Julie M.
Tawbi, Hussein A.
McQuade, Jennifer
Hwu, Patrick
Hwu, Wen-Jen
[J]. NATURE MEDICINE, 2021, 27 (08) : 1432 - +
[10] Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
Mangsbo, Sara M.
Sandin, Linda C.
Anger, Kerstin
Korman, Alan J.
Loskog, Angelica
Totterman, Thomas H.
[J]. JOURNAL OF IMMUNOTHERAPY, 2010, 33 (03) : 225 - 235

← 1 2 3 4 5 →